4th Annual Molecular Imaging in Drug Discovery and Development
Integrating Molecular Imaging Technologies to Improve Preclinical Findings
Molecular Imaging in Drug Discovery and Development is designed to bring together leading molecular imaging experts from industry and academia, as well as scientists who use their services to accelerate the research. Cancer, drug toxicity, pain and formulation are the main areas of application that will be discussed at the meeting.
Recommended Short Courses*
* Separate registration required
Tuesday, June 4
7:45 am Registration and Morning Coffee
LATEST TECHNOLOGICAL ADVANCES
8:30 Chairperson's Opening Remarks
8:40 The Power of Imaging in Drug Discovery
Thomas Bocan, Ph.D., Senior Director, Preclinical Imaging, Pharmatherapeutics Precision Medicine, Worldwide Research & Development, Pfizer, Inc.
9:10 New Developments in CT Imaging: Novel, Nanoparticle Contrast Media, Multi-Energy Scanners and Iterative Reconstruction
David Cormode, Ph.D., Assistant Professor, Radiology, University of Pennsylvania
In the past five years the field of nanoparticle CT contrast agents has rapidly grown. This is starting to allow molecular imaging with CT. In addition, CT scanner technology is improving to allow specific and sensitive detection of contrast media. This presentation will cover the recent advances in the field and offer a perspective on future developments.
9:40 Molecular and Cellular MRI
Erik M. Shapiro, Ph.D., Research Director, Department of Radiology, Michigan State University
This presentation will cover: MRI contrast agents for Molecular and Cellular MRI; Strategies for using targeted contrast agents for Molecular MRI of cancer and other pathologies; Magnetic cell labeling and MRI-based cell tracking; Quantification schemes for Molecular and Cellular MRI; A path towards clinical translation for experimental Molecular and Cellular MRI paradigms.
10:10 Coffee Break
10:40 Emerging Technologies in Imaging Quantitation
James Gee, Ph.D., Professor and Director, Penn Image and Computing Science Laboratory, University of Pennsylvania
Additional Instructors to be Announced
11:10 Nature-Derived Nanoparticles for Targeted Diagnosis and Therapy
Willem Mulder, Ph.D., Associate Professor of Radiology, Director, Nanomedicine Program, Translational and Molecular Imaging Institute, Mount Sinai School of Medicine
Lipoproteins, natural nanoparticles that function as fat transporters in the human body, can be used as models to create multifunctional nanoparticles that inherently have specificity for atherosclerosis. Chemical modifications can be introduced to alter their specificity and reroute such nanoparticles to other epitopes and diseases of interest. The payload of lipoprotein-derived nanoparticles may vary from small hydrophobic or amphiphilic molecules to hydrophobically coated nanocrystals, to introduce diagnostic and/or therapeutic features.
11:40 Sponsored Presentation (Opportunity Available)
12:10 pm Luncheon Presentation (Opportunity Available)
3:00 Grand Opening of the Exhibit Hall with Poster Viewing
4:00 Fluorine-18 Chemistry Fuel the Discovery of Novel PET Tracers
Scott Edwards, Ph.D., Vice President and General Manager, R&D, SciFluor Life Sciences, LLC
Innovative methodologies aimed at improving the selectivity and yield for the incorporation of F-18 into small molecules, peptides, and small proteins are thus an active area of research, including: metal-assisted electrophilic fluorination; “Click - chemistry, and fluorophilic bifunctional chelators for directly labeling biologics. This presentation will review the new F-18 methodologies and provide perspective on their application in the synthesis of new tracers as translational research and development tools.
4:30 Panel Discussion: The Future of Molecular Imaging in Drug Discovery and Development
Moderator: Erik M. Shapiro, Ph.D., Research Director, Department of Radiology, Michigan State University
5:00 Sponsored Presentation (Opportunity Available)
5:30 Welcome Reception in the Exhibit Hall with Poster Viewing
6:30 Close of Day